logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
D

David A. Sallman

h lee moffitt cancer center
H指数:46
被引数:9,121

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Oral Azacitidine Maintenance After CPX-351 in Transplant-Ineligible Patients With Therapy-Related or Myelodysplasia-Related Acute Myeloid Leukemia

在移植不适宜的继发性或骨髓增生异常综合征相关急性髓系白血病患者中，CPX-351治疗后口服阿扎胞苷维持治疗

American Journal of Hematology
IF9.9
2026-10-120
OAAI
Caroline Fileni; Edmond Chiche; David Swoboda; Alexander Coltoff; Rami Komrokji; Geoffrey Uy; Sarah Bertoli; Lenaig Le Clech; Mael Heiblig; Ludovic Gabellier; Patrick Lawrence; Lydia Kretschmer; Christoph Röllig; A. H. Wei; Fabio Guolo; Roberto Massimo Lemoli; Jeffrey Lancet; David Sallman; Thomas Cluzeau
Correction: spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms

更正：骨髓空间结构的重塑定义了骨髓增生异常性肿瘤中疾病活动性和治疗反应的组织状态特征

Leukemia
IF13.4
2026-10-070
OAAI
Ryan Nachman; Aleksandra Kopacz; Caitlin Unkenholz; Jiani Chai; Arvin Ruiz; Itzel Valencia; Jeanne Jiang; Fabio Socciarelli; Jiwoon Park; Christopher E. Mason; Ling Zhang; David Sallman; Gail J. Roboz; Pinkal Desai; Justin Kaner; Joshua Fein; Monica Guzman; Neal Lindeman; Amy Chadburn; Madhu Ouseph; Paul Simonson; Julia Geyer; Giorgio Inghirami; Shahin Rafii; David Redmond; Sanjay S. Patel
Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia

I期剂量递增和扩展试验：双特异性CD47抑制剂和CD40激动剂Fc融合蛋白SL-172154（SIRPα-Fc-CD40L）在具有高风险骨髓增生异常综合征或急性髓系白血病患者中的应用

Cancer
IF5.1
2026-10-050
OAAI
Naval G. Daver MD; Amer M. Zeidan MD; Anthony S. Stein MD; Joshua F. Zeidner MD; Keri Maher DO; Emily Curran MD; Dale Bixby MD, PhD; Wanxing Chai-Ho MD; Maximilian Stahl MD; Karen W. L. Yee MD; Don Stevens MD; Sawa Ito MD, PhD; Jana Reynolds MD; Patrick Medd MD, PhD; Emma Searle MD, PhD; Andrew Sochacki MD; Mary Lynn Savoie MD; Steven Green MD; Kazunobu Kato MD, PhD; Robert Hernandez PhD; Simon Metenou PhD; Bo Ma PhD; Lini Pandite MD; Taylor H. Schreiber MD, PhD; David A. Sallman MD
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

基于低甲基化制剂治疗的反应对高风险骨髓增生异常综合征/肿瘤患者生存结局的影响：考虑基线临床-分子风险和移植状态的国际骨髓增生异常综合征联盟(icMDS)分析

American Journal of Hematology
IF9.9
2026-08-280
PRE
Benjamin Rolles; Jan Philipp Bewersdorf; Tariq Kewan; Ondrej Blaha; Jessica M. Stempel; Luca Lanino; Najla H. Al Ali; Amy E. DeZern; Mikkael A. Sekeres; Geoffrey L. Uy; Samuel Urrutia; Hetty E. Carraway; Pinkal Desai; Elizabeth A. Griffiths; Eytan M. Stein; Andrew M. Brunner; Christine McMahon; Rory M. Shallis; Joshua F. Zeidner; Michael R. Savona; Shougat Barua; Namrata Sonia Chandhok; Constantine Logothetis; Aram Bidikian; Ted M. Getz; Gail J. Roboz; Eunice S. Wang; Amyah C. Harris; Maria L. Amaya; Hayley Hawkins; Somedeb Ball; Justin Grenet; Parisa Abedi; Shai Shimony; R. Coleman Lindsley; Zhuoer Xie; Yazan F. Madanat; Yasmin Abaza; Talha Badar; Torsten Haferlach; Jaroslaw P. Maciejewski; David Sallman; Anoop Enjeti; Kamal Al-Rabi; Khalid Halahleh; Devendra Hiwase; Maria Diez-Campelo; David Valcarcel; Claudia Haferlach; Lisa Pleyer; Ioannis Kotsianidis; Vasiliki Pappa; Valeria Santini; Angela Consagra; Aref Al-Kali; Seishi Ogawa; Yasuhito Nannya; Matteo Giovanni Della Porta; Rami S. Komrokji; Amer M. Zeidan; Maximilian Stahl
Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms

骨髓空间结构重塑定义了骨髓增生异常综合征中疾病活动度和治疗反应的组织状态特征

Leukemia
IF13.4
2026-06-300
OA
Ryan Nachman; Aleksandra Kopacz; Caitlin Unkenholz; Jian Chai; Arvin Ruiz; Itzel Valencia; Jeanne Jiang; Fabio Socciarelli; Jiwoon Park; Christopher E. Mason; Ling Zhang; David Sallman; Gail J. Roboz; Pinkal Desai; Justin Kaner; Joshua Fein; Monica Guzman; Neal Lindeman; Amy Chadburn; Madhu Ouseph; Paul Simonson; Julia Geyer; Giorgio Inghirami; Shahin Rafii; David Redmond; Sanjay S. Patel
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database

高风险骨髓增生异常综合征/新生物患者接受去甲基化药物+维奈克拉治疗后的结局分析——国际骨髓增生异常综合征（icMDS）VALIDATE数据库分析

Blood Cancer Journal
IF11.6
2026-06-290
OAAI
Jan Philipp Bewersdorf; Tariq Kewan; Luca Lanino; Wei Wei; Tulika Rudra Gupta; Jessica M. Stempel; Najla H. Al Ali; Amy E. DeZern; Mikkael A. Sekeres; Geoffrey L. Uy; Samuel Urrutia; Hetty E. Carraway; Pinkal Desai; Elizabeth A. Griffiths; Eytan M. Stein; Andrew M. Brunner; Christine McMahon; Rory M. Shallis; Joshua F. Zeidner; Michael R. Savona; Hayley Hawkins; Namrata Sonia Chandhok; Constantine N. Logothetis; Aram Bidikian; Ted M. Getz; Gail J. Roboz; Benjamin Rolles; Eunice S. Wang; Amyah C. Harris; Maria L. Amaya; Somedeb Ball; Justin Grenet; Zhuoer Xie; Yazan F. Madanat; Yasmin Abaza; Talha Badar; Jaclynn Campos; Torsten Haferlach; Jaroslaw P. Maciejewski; David Sallman; Anoop Enjeti; Kamal Al-Rabi; Khalid Halahleh; Devendra Hiwase; Maria Diez-Campelo; David Valcarcel; Claudia Haferlach; Lisa Pleyer; Ioannis Kotsianidis; Vassiliki Pappa; Valeria Santini; Angela Consagra; Aref Al-Kali; Seishi Ogawa; Yasuhito Nannya; Maximilian Stahl; Matteo Giovanni Della Porta; Rami S. Komrokji; Amer M. Zeidan
Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution

基于分子演化的骨髓增生异常综合征预后评分

NEJM Evidence
IF0
2026-05-262
PRE
Civettini, Ivan; Malighetti, Federica; Villa, Matteo; Crippa, Valentina; Aroldi, Andrea; Cavalca, Fabrizio; Graudenzi, Alex; Lanino, Luca; Maggioni, Giulia; Haferlach, Torsten; Fenaux, Pierre; Platzbecker, Uwe; Diez-Campelo, Maria; Borin, Lorenza Maria; Fumagalli, Monica; Zappaterra, Arianna; Manghisi, Beatrice; Al Ali, Najla H.; Sallman, David A.; Padron, Eric; Xie, Zhuoer; Chan, Onyee; Zeidan, Amer M.; Mologni, Luca; Piazza, Rocco; Komrokji, Rami S.; Della Porta, Matteo Giovanni; Gambacorti-Passerini, Carlo; Ramazzotti, Daniele
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study

TP53突变髓系肿瘤中≥5%原始细胞染色体5异常的表征：一项国际TP53研究者网络(iTiN)研究

Cancer
IF5.1
2026-01-010
OAAI
Yasin, Irfan; Stengel, Anna; Shao, Haipeng; Kaur, Amandeep; Mason, Emily F.; Patwardhan, Pranav P.; Bailey, Nathanael G.; Ghosh, Sharmila; Inamdar, Kedar V.; Patel, Anand A.; Pandiri, Madhavi; Zhang, Jingjing; Sojitra, Payal; Tariq, Hamza; Pan, Zenggang; Wiredja, Danica; Wang, Peng; Tjota, Melissa Y.; Segal, Jeremy P.; Chang, Hong; Sallman, David A.; Arber, Daniel A.; Tefferi, Ayalew; Badar, Talha; Perry, Anamarija M.; Haferlach, Claudia; Lager, Angela M.; Venkataraman, Girish
Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes

移植后微小残留病（MRD）通过TP53双测序结合APR-246 + 去氧氟尿苷维持治疗预测预后

Blood Advances
IF7.1
2025-11-270
OAAI
David A. Sallman; Amy F. McLemore; Rami Komrokji; Hany Elmariah; Andrew T. Kuykendall; Nelli Bejanyan; Onyee Chan; Rawan Faramand; Joseph Pidala; Sean J. Yoder; Lia Perez; Taiga Nishihori; Eric Padron; Hugo Fernandez; Jeffrey E. Lancet; Asmita Mishra
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia

MICA/MICB的下调增强了NKG2DL CAR T细胞在复发或难治性急性髓系白血病或骨髓异常增生性肿瘤患者中的细胞持久性和临床活性。

Leukemia
IF13.4
2025-09-150
PRE
Daniel Pollyea; Tessa Kerre; Dries Deeren; Yves Beguin; Tara L. Lin; David A. Sallman; Sebastien Anguille; William G. Blum; Anne Flament; Eytan Breman; Caroline Lonez
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia

去甲基化药物与Venetoclax联合方案是老年（≥70岁）新诊断低危急性髓系白血病患者接受强化化疗的安全有效替代方案。

American Journal of Hematology
IF9.9
2025-08-070
PREAI
Somedeb Ball; Akriti G. Jain; Najla Al Ali; Luis E. Aguirre; Jan Philipp Bewersdorf; Andrew Kent; Ameera Rose; Alexander Hayden; Alexa Siddon; Jill Lykon; Ellen Madarang; David M. Swoboda; Eric Padron; Kendra Sweet; David A. Sallman; Jeffrey Lancet; Hetty E. Carraway; Justin Watts; Amer Zeidan; Daniel A. Pollyea; Rami S. Komrokji
XPO1 Drives Resistance to Eprenetapopt and Azacitidine and Can Be Targeted in TP53 Mutated Myeloid Malignancies

XPO1驱动对Eprenetapopt和Azacitidine的抵抗，并且可以在TP53突变的髓系恶性疾病中作为靶点

Blood
IF23.1
2025-08-050
PRE
Traci L. Kruer; Ariel Quintana; Hannah Newman; Meghan Ferrall-Fairbanks; Ling Zhang; Amy McLemore; Surendra Neupane; Qin Yang; Nana Adjoa Ben-Crentsil; Maria E. Balasis; Christopher Letson; Rami Komrokji; Sana Chaudhry; Tulasigeri M. Totiger; Joshua Traina; Maria E. Figueroa; Christopher B. Ryder; Thomas Cluzeau; Justin Taylor; David A. Sallman; Eric Padron
Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes

多个TET2突变在骨髓增生异常和骨髓增生性慢性粒单核细胞白血病亚型中均带来额外的生存益处

Leukemia
IF13.4
2025-06-240
PRE
Clifford M. Csizmar; Anuya Natu; Mark Gurney; Saubia Fathima; Ali Khalid A. Alsugair; Rashmi Kanagal-Shamanna; Sanam Loghavi; Alexandre Bazinet; Kelly Chien; Danielle Hammond; Courtney DiNardo; Tapan Kadia; Farhad Ravandi-Kashani; Naveen Pemmaraju; Koji Sasaki; Terra L. Lasho; Christy M. Finke; Aref Al-Kali; Hassan Alkhateeb; Kebede Begna; Naseema Gangat; Mehrdad Hefazi Torghabeh; Aasiya Matin; Abhishek A. Mangaonkar; Antoine N. Saliba; Ayalew Tefferi; Guillermo Garcia-Manero; Hagop M. Kantarjian; Rami S. Komrokji; Zhuoer Xie; Najla A. Ali; David Sallman; Eric Padron; Guillermo Montalban-Bravo; Mrinal M. Patnaik
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS

他米巴罗替与阿扎胞苷联合治疗新诊断高危骨髓增生异常综合征（MDS）的SELECT-MDS-1三期研究的关键结果

Blood Advances
IF7.1
2025-05-090
OAAI
Amy E. DeZern; Sylvain Thepot; Stephane de Botton; Andrea Patriarca; Dries Deeren; Jose-Miguel Torregrossa-Diaz; Giovanni Marconi; Teresa Bernal; Juan Bergua Burgues; Blanca Xicoy; Anna Jonášová; Amer M. Zeidan; Sophie Dimicoli-Salazar; Célestine Simand; David Valcarcel; Maria Diez Campelo; Wanxing Chai-Ho; Lalit Saini; Alice Garnier; Klaus Geissler; Yishai Ofran; Zsolt Nagy; Pramila Krishnamurthy; Michael Lübbert; Grzegorz Basak; Hetty E. Carraway; David A. Sallman; Uma Borate; Valeria Santini; Victoria Campbell; Pierre Fenaux; Thorsten Braun; Francesco Lanza; Jan Maciej Zaucha; David A. Roth; Sofia Paul; Pourab Roy; Michael J. Kelly; Angela Volkert; Jaime Chisholm; Tanya Abdul Malak; Virginia M. Klimek; Thomas Cluzeau

研究方向

暂未获取到该数据
R
Rami S. Komrokji
H 指数:68论文数:1,498被引数:1.8万
E
Eric Padron
H 指数:53论文数:903被引数:1.5万
J
Jeffrey E. Lancet
H 指数:62论文数:881被引数:1.5万
O
Onyee Chan
H 指数:19论文数:306被引数:1,812
A
Alan F. List
H 指数:89论文数:1,027被引数:3.5万
K
Kendra Sweet
H 指数:35论文数:374被引数:5,604
A
Andrew Kuykendall
H 指数:25论文数:581被引数:2,851
Z
Zhuoer Xie
H 指数:20论文数:224被引数:3,565
N
Najla Al Ali
H 指数:23论文数:251被引数:2,046
N
Najla H. Al Ali
H 指数:24论文数:187被引数:2,481